{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:19:16Z","timestamp":1792603156042,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"publisher","award":["5R13MH064074"],"award-info":[{"award-number":["5R13MH064074"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["schres-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.schres.2014.04.037","type":"journal-article","created":{"date-parts":[[2014,5,28]],"date-time":"2014-05-28T01:47:16Z","timestamp":1401241636000},"page":"84-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia"],"prefix":"10.1016","volume":"157","author":[{"given":"Maju Mathew","family":"Koola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anilkumar","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine J.","family":"Aitchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Weinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Aaronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith B.","family":"Dickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2014.04.037_bb0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neuroscience.2013.01.063","article-title":"Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine","volume":"238","author":"Alexander","year":"2013","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.schres.2014.04.037_bb0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/WAD.0b013e31816653bc","article-title":"Long-term course and effectiveness of combination therapy in Alzheimer disease","volume":"22","author":"Atri","year":"2008","journal-title":"Alzheimer Dis. Assoc. Disord."},{"issue":"1","key":"10.1016\/j.schres.2014.04.037_bb0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/alzrt160","article-title":"Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy","volume":"5","author":"Atri","year":"2013","journal-title":"Alzheimers Res. Ther."},{"issue":"11","key":"10.1016\/j.schres.2014.04.037_bb0020","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s002590000372","article-title":"Imaging the glutamatergic system in vivo\u2014relevance to schizophrenia","volume":"27","author":"Bressan","year":"2000","journal-title":"Eur. J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.schres.2014.04.037_bb0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/schbul\/sbi020","article-title":"A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia","volume":"31","author":"Buchanan","year":"2005","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2014.04.037_bb0030","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/schbul\/sbm083","article-title":"Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia","volume":"33","author":"Buchanan","year":"2007","journal-title":"Schizophr. Bull."},{"issue":"10","key":"10.1016\/j.schres.2014.04.037_bb0035","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1176\/appi.ajp.2007.06081358","article-title":"The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments","volume":"164","author":"Buchanan","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2014.04.037_bb0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1176\/appi.ajp.2007.07050724","article-title":"Galantamine for the treatment of cognitive impairments in people with schizophrenia","volume":"165","author":"Buchanan","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2014.04.037_bb0045","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2165\/00023210-200317090-00004","article-title":"The glutamatergic system and Alzheimer's disease: therapeutic implications","volume":"17","author":"Butterfield","year":"2003","journal-title":"CNS Drugs"},{"issue":"2\u20133","key":"10.1016\/j.schres.2014.04.037_bb0050","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0165-0173(99)00050-8","article-title":"Network interactions in schizophrenia \u2014 therapeutic implications","volume":"31","author":"Carlsson","year":"2000","journal-title":"Brain Res. Brain Res. Rev."},{"issue":"3","key":"10.1016\/j.schres.2014.04.037_bb0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J. Med. Chem."},{"issue":"1\u20133","key":"10.1016\/j.schres.2014.04.037_bb0060","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2006.07.011","article-title":"A model of anticholinergic activity of atypical antipsychotic medications","volume":"88","author":"Chew","year":"2006","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2014.04.037_bb0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejphar.2003.08.105","article-title":"The genetics of schizophrenia: glutamate not dopamine?","volume":"480","author":"Collier","year":"2003","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.schres.2014.04.037_bb0070","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/1568007024606212","article-title":"Ionotropic glutamate receptors as therapeutic targets in schizophrenia","volume":"1","author":"Coyle","year":"2002","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"issue":"10","key":"10.1016\/j.schres.2014.04.037_bb0075","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4088\/JCP.08m04935gry","article-title":"Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine","volume":"70","author":"de Lucena","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2014.04.037_bb0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00213-004-2109-y","article-title":"Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia","volume":"179","author":"Egerton","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"issue":"1\u20132","key":"10.1016\/j.schres.2014.04.037_bb0085","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0304-3940(01)02242-X","article-title":"Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia","volume":"313","author":"Erhardt","year":"2001","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.schres.2014.04.037_bb0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.WNF.0000240940.67241.F6","article-title":"Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study","volume":"30","author":"Fagerlund","year":"2007","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.schres.2014.04.037_bb0095","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s00213-005-2235-1","article-title":"Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial","volume":"181","author":"Freudenreich","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"10.1016\/j.schres.2014.04.037_bb0100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-3223(01)01342-7","article-title":"A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia","volume":"51","author":"Friedman","year":"2002","journal-title":"Biol. Psychiatry"},{"issue":"5500","key":"10.1016\/j.schres.2014.04.037_bb0105","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1126\/science.290.5500.2315","article-title":"Cholinergic enhancement and increased selectivity of perceptual processing during working memory","volume":"290","author":"Furey","year":"2000","journal-title":"Science"},{"issue":"7 Suppl. 1","key":"10.1016\/j.schres.2014.04.037_bb0110","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1177\/0091270006288734","article-title":"Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease","volume":"46","author":"Geerts","year":"2006","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.schres.2014.04.037_bb0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1176\/appi.ajp.2007.07010089","article-title":"Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study","volume":"165","author":"Green","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2014.04.037_bb0120","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1471-4906(03)00072-3","article-title":"Tolerance, DCs and tryptophan: much ado about IDO","volume":"24","author":"Grohmann","year":"2003","journal-title":"Trends Immunol."},{"issue":"7 Suppl. 1","key":"10.1016\/j.schres.2014.04.037_bb0125","doi-asserted-by":"crossref","first-page":"17S","DOI":"10.1177\/0091270006288735","article-title":"Rationale for combination therapy with galantamine and memantine in Alzheimer's disease","volume":"46","author":"Grossberg","year":"2006","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.schres.2014.04.037_bb0130","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.biopsych.2004.12.037","article-title":"D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia","volume":"57","author":"Heresco-Levy","year":"2005","journal-title":"Biol. Psychiatry"},{"issue":"19","key":"10.1016\/j.schres.2014.04.037_bb0135","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1523\/JNEUROSCI.21-19-07463.2001","article-title":"The brain metabolite kynurenic acid inhibits \u03b17 nicotinic receptor activity and increases non-\u03b17 nicotinic receptor expression: physiopathological implications","volume":"21","author":"Hilmas","year":"2001","journal-title":"J. Neurosci."},{"issue":"43","key":"10.1016\/j.schres.2014.04.037_bb0140","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1523\/JNEUROSCI.2213-07.2007","article-title":"NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons","volume":"27","author":"Homayoun","year":"2007","journal-title":"J. Neurosci."},{"issue":"11","key":"10.1016\/j.schres.2014.04.037_bb0145","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"Hopkins","year":"2008","journal-title":"Nat. Chem. Biol."},{"issue":"10","key":"10.1016\/j.schres.2014.04.037_bb0150","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2014.04.037_bb0155","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.npp.1301499","article-title":"Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo\/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial","volume":"33","author":"Keefe","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.schres.2014.04.037_bb0160","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1176\/appi.ajp.2007.07010043","article-title":"The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization","volume":"165","author":"Kern","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2014.04.037_bb0165","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.schres.2010.11.008","article-title":"The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study","volume":"126","author":"Kern","year":"2011","journal-title":"Schizophr. Res."},{"issue":"9","key":"10.1016\/j.schres.2014.04.037_bb0170","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jpsychires.2013.04.013","article-title":"NMDA receptor antagonists interventions in schizophrenia: meta-analysis of randomized, placebo-controlled trials","volume":"47","author":"Kishi","year":"2013","journal-title":"J. Psychiatr. Res."},{"issue":"12","key":"10.1016\/j.schres.2014.04.037_bb0175","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/NMD.0b013e3182392d8f","article-title":"Case report on the management of depression in schizoaffective disorder, bipolar type focusing on lithium levels and measurement-based care","volume":"199","author":"Koola","year":"2011","journal-title":"J. Nerv. Ment. Dis."},{"issue":"1","key":"10.1016\/j.schres.2014.04.037_bb0180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/2045125313500982","article-title":"High-dose prazosin for the treatment of post-traumatic stress disorder","volume":"4","author":"Koola","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2014.04.037_bb0185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.schres.2014.04.037_bb0195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0169-328X(00)00274-6","article-title":"The effect of nicotine and haloperidol co-treatment on nicotinic receptor levels in the rat brain","volume":"86","author":"Lee","year":"2001","journal-title":"Brain Res. Mol. Brain Res."},{"issue":"2","key":"10.1016\/j.schres.2014.04.037_bb0200","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e3280117feb","article-title":"A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia","volume":"22","author":"Lee","year":"2007","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2014.04.037_bb0190","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4306\/pi.2012.9.2.166","article-title":"Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study","volume":"9","author":"Lee","year":"2012","journal-title":"Psychiatry Invest."},{"issue":"5","key":"10.1016\/j.schres.2014.04.037_bb0205","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/npp.2008.200","article-title":"A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia","volume":"34","author":"Lieberman","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"2\u20133","key":"10.1016\/j.schres.2014.04.037_bb0210","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.schres.2010.08.021","article-title":"Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia","volume":"125","author":"Lindenmayer","year":"2011","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2014.04.037_bb0215","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/brb3.118","article-title":"Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity","volume":"3","author":"Lopes","year":"2013","journal-title":"Brain Behav."},{"issue":"13","key":"10.1016\/j.schres.2014.04.037_bb0220","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1523\/JNEUROSCI.22-13-05462.2002","article-title":"Control of feedforward dendritic inhibition by NMDA receptor-dependent spike timing in hippocampal interneurons","volume":"22","author":"Maccaferri","year":"2002","journal-title":"J. Neurosci."},{"issue":"8","key":"10.1016\/j.schres.2014.04.037_bb0225","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00228-004-0825-1","article-title":"Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions","volume":"60","author":"Micuda","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.schres.2014.04.037_bb0230","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J. Neurosci."},{"issue":"3\u20134","key":"10.1016\/j.schres.2014.04.037_bb0235","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.drudis.2006.12.006","article-title":"Fragments, network biology and designing multiple ligands","volume":"12","author":"Morphy","year":"2007","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.schres.2014.04.037_bb0240","first-page":"303","article-title":"Neuroreceptor changes in Alzheimer disease","volume":"4","author":"Nordberg","year":"1992","journal-title":"Cerebrovasc. Brain Metab. Rev."},{"issue":"2","key":"10.1016\/j.schres.2014.04.037_bb0245","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2014.04.037_bb0250","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1096\/fasebj.4.10.2165009","article-title":"Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic?","volume":"4","author":"Palmer","year":"1990","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.schres.2014.04.037_bb0255","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0022-3565(24)37160-5","article-title":"Novel systemically active antagonists of the glycine site of the N-methyl-d-aspartate receptor: electrophysiological, biochemical and behavioral characterization","volume":"283","author":"Parsons","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.schres.2014.04.037_bb0260","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.neuropharm.2007.07.013","article-title":"Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system\u2014too little activation is bad, too much is even worse","volume":"53","author":"Parsons","year":"2007","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.schres.2014.04.037_bb0265","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","article-title":"Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease","volume":"24","author":"Parsons","year":"2013","journal-title":"Neurotox. Res."},{"issue":"6","key":"10.1016\/j.schres.2014.04.037_bb0270","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s12603-012-0062-8","article-title":"A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI","volume":"16","author":"Peters","year":"2012","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.schres.2014.04.037_bb0275","series-title":"Naltrexone and Prazosin Combination for Posttraumatic Stress Disorder and Alcohol Use Disorder. The Primary Care Companion for CNS Disorders","author":"Qazi","year":"2014"},{"issue":"3","key":"10.1016\/j.schres.2014.04.037_bb0280","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1527-3458.2003.tb00254.x","article-title":"The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease","volume":"9","author":"Rogawski","year":"2003","journal-title":"CNS Drug Rev."},{"issue":"3","key":"10.1016\/j.schres.2014.04.037_bb0285","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1124\/jpet.102.045773","article-title":"Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors","volume":"305","author":"Samochocki","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.schres.2014.04.037_bb0290","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1124\/mol.61.5.1222","article-title":"The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system","volume":"61","author":"Santos","year":"2002","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.schres.2014.04.037_bb0295","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.npp.1301087","article-title":"Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors","volume":"32","author":"Schilstrom","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.schres.2014.04.037_bb0300","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.biopsych.2006.04.006","article-title":"Galantamine improves cognition in schizophrenic patients stabilized on risperidone","volume":"60","author":"Schubert","year":"2006","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2014.04.037_bb0305","first-page":"163","article-title":"What is the recommended approach to asymptomatic patients who develop a reactive PPD?","volume":"55","author":"Sharma","year":"2006","journal-title":"J. Fam. Pract."},{"issue":"22","key":"10.1016\/j.schres.2014.04.037_bb0310","doi-asserted-by":"crossref","first-page":"9708","DOI":"10.1021\/jm3009458","article-title":"Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease","volume":"55","author":"Simoni","year":"2012","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.schres.2014.04.037_bb0315","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1185\/030079907X233403","article-title":"A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch","volume":"23","author":"Small","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"10.1016\/j.schres.2014.04.037_bb0320","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0031-6997(25)00441-7","article-title":"Neuropharmacology of quinolinic and kynurenic acids","volume":"45","author":"Stone","year":"1993","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.schres.2014.04.037_bb0325","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.schres.2014.04.037_bb0330","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev.pharmtox.42.082701.160735","article-title":"Glutamatergic mechanisms in schizophrenia","volume":"42","author":"Tsai","year":"2002","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.schres.2014.04.037_bb0335","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1017\/S1461145703004024","article-title":"A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia","volume":"7","author":"Tugal","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2014.04.037_bb0340","doi-asserted-by":"crossref","first-page":"H977","DOI":"10.1152\/ajpheart.00837.2004","article-title":"Acute vagotomy activates the cholinergic anti-inflammatory pathway","volume":"288","author":"van Westerloo","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"9","key":"10.1016\/j.schres.2014.04.037_bb0345","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1176\/appi.ajp.2009.09010017","article-title":"The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia","volume":"166","author":"Vinogradov","year":"2009","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.schres.2014.04.037_bb0350","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.mrfmmm.2006.11.030","article-title":"Genetic evidence for ongoing balanced selection at human DNA repair genes ERCC8, FANCC, and RAD51C","volume":"616","author":"Wang","year":"2007","journal-title":"Mutat. Res."},{"issue":"12","key":"10.1016\/j.schres.2014.04.037_bb0355","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0024-3205(00)00411-2","article-title":"No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use","volume":"66","author":"Wenk","year":"2000","journal-title":"Life Sci."},{"issue":"1\u20133","key":"10.1016\/j.schres.2014.04.037_bb0360","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.schres.2014.01.006","article-title":"Chronic and bedtime use of benztropine with antipsychotics: is it necessary?","volume":"153","author":"Wijegunaratne","year":"2014","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2014.04.037_bb0365","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/schbul\/sbq002","article-title":"Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia","volume":"36","author":"Wonodi","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2014.04.037_bb0370","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1177\/1073858405279692","article-title":"Targeting prefrontal cortical dopamine D1 and N-methyl-d-aspartate receptor interactions in schizophrenia treatment","volume":"11","author":"Yang","year":"2005","journal-title":"Neuroscientist"},{"issue":"5","key":"10.1016\/j.schres.2014.04.037_bb0375","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/0091270005274551","article-title":"Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects","volume":"45","author":"Yao","year":"2005","journal-title":"J. Clin. Pharmacol."},{"issue":"7\u20138","key":"10.1016\/j.schres.2014.04.037_bb0380","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.neuropharm.2006.08.007","article-title":"In vitro galantamine\u2013memantine co-application: mechanism of beneficial action","volume":"51","author":"Zhao","year":"2006","journal-title":"Neuropharmacology"},{"issue":"1\u20132","key":"10.1016\/j.schres.2014.04.037_bb0385","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discov. Today"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414002321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414002321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T04:25:32Z","timestamp":1746246332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996414002321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":77,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0920996414002321"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2014.04.037","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2014.04.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}